Close

FDA approves Paragonix’s next generation donor lung preservation system

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

UK Life Sciences Sector Plan Eases Startup Regulations

How the UK Life Sciences Sector Plan Reduces Regulatory...

The US FDA has granted approval for Paragonix Technologies’ next-generation donor lung preservation system, BAROguard.

The system integrates the company’s advanced hypothermic preservation technology with automated, continuous and active control of airway pressure.

This guarantees the maintenance of an optimal temperature range and a clinically recommended range of inflation pressure for donor lungs throughout the transportation from donor to recipient patient.

In the present clinical practice, donor lungs are preserved and transported in an inflated state from the donor to the recipient site.

The existing methods for organ recovery fail to maintain and control lung inflation pressures within the clinically recommended 12cm-15cm H₂O range.

A large portion of donor lungs are transported by aircraft. This method of transportation is said to expose the lungs to potential pressure changes due to the varying ambient conditions.

This increase in pressure has been observed in studies on respiratory care and it raises the possibility of a greater risk for pulmonary barotrauma.

Paragonix CEO and president Dr Lisa Anderson said: “At Paragonix, we believe that transplant surgeons should have maximum control over the organ transplant process.

“BAROguard now offers automated active control over donor lung airway pressures and automated donor lung temperature control, both of which are continuously reported in real-time to the transplant team.

“The FDA clearance of BAROguard is a major step in providing transplant teams with leading technology to enhance organtransplantation outcomes.”

Latest stories

Related stories

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

UK Life Sciences Sector Plan Eases Startup Regulations

How the UK Life Sciences Sector Plan Reduces Regulatory...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back